As a leading service provider in the field of antibody discovery and immunotherapy for years, Creative Biolabs can provide customers with professional bispecific T-cell receptor (TCR) development service in a de novo manner. Bispecific TCR is a molecule that can regulate the body’s immune system by redirecting and promote the T-cell response towards cancer cells with specific tumor targets.
The TCR is a molecule existed on the surface of T cells, or T lymphocytes. Its responsibility is to recognize fragments of antigen to provide peptides bound to major histocompatibility complex (MHC) molecules. The relationship between the binding TCR and antigen peptides is unrestricted and gradually degenerated, which means that TCRs and antigen peptide are not in a biunique relationship. Typically, the TCR is made up of two different protein chains. After being combined with antigenic peptide and MHC (peptide/MHC complex) via TCR, the T lymphocyte will be activated through signal transduction. This is a series of biochemical events mediated by associated enzymes, co-receptors, and specialized adaptor molecules, resulting in activation of transcription factors.
Introduction of Bispecific TCR
Bispecific TCR molecules can leverage the body’s immune system by regulating the T-cell response towards cancer cells with specific tumor targets. There are two domains of our bispecific T-cell receptor. One of them is an affinity-maturated and highly selective TCR domain that can recognize and bind to a tumor-specific peptide target presented in the context of HLA class I receptor, the other is a T-cell recruiting antibody domain directed against CD3 or other immuno-modulating T-cell surface proteins. The characteristic of these novel receptors allows T cells to be activated and attack the tumor, regardless of the T cells’ intrinsic specificity. After being administrated to the patients, our bispecific TCR will selectively bind to the surface of targeted tumor cells. Then the bispecific TCR will recruit and activate T cells via CD3 binding initiates tumor killing.
Fig 1. Antigen presentation stimulates T cells with the help of TCR.
Features of Our Service
Creative Biolabs is a leader in the field of immunotherapy with great reputation and experience. We now provide professional and advanced platform to a large number of customers around the world, giving them timely assistance to complete each project successfully. We take the responsibility to promote your projects and lead the progress to clinical trials with the help of our advanced technologies and resources. For more detail information, please feel free to contact us. We will get back to you as soon as possible.
For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy with the complete TCR without HLA dependence.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE